Baricitinib, approved for RA treatment, is a potent inhibitor of JAK1 and JAK2 with a 100-fold affinity for JAK1 and JAK2 over JAK3; therefore, it also has some activities on IL-3 and IL-5 [25]. Here, JAK1 is linked to rheumatoid arthritis.